Amniotic fluid stem cells (AFSCs) appear to be a valuable alternative to both embryonic and adult stem cells, offering a new approach to tissue repair and regenerative medicine. Stem cells were discovered in amniotic fluid donated by pregnant women in 2007, representing a novel and ground-breaking finding in the field. Since then, it has become well known that AFSCs are readily available via routine antenatal testing (i.e., amniocenteses). AFSCs also appear to be much more pluripotent (i.e., able to generate a broad range of cell types) than adult stem cells,
yet do not involve harming or destroying life at any stage, thus avoiding the ethical dilemma associated with the use of embryonic stem cells.
Amniotic fluid stem cells, which are shed mostly from skin of the developing fetus, can be safely obtained and are routinely harvested from pregnant women undergoing antenatal testing (i.e., amniocentesis) at about 15 weeks of pregnancy. While amniocentesis, which is performed by inserting a needle through the abdomen into the amniotic sac to extract amniotic fluid, is not risk-free, it is often performed during the fourth to sixth months of pregnancy to detect birth defects. Typically, more cells than are actually needed for the test are collected, and AFSCs can 
